UNLABELLED: Murine models of autoimmunity allow the study of the earliest events in disease pathogenesis. Our laboratory has developed a xenobiotic induced model of primary biliary cirrhosis (PBC) following immunization of mice with 2-octynoic acid coupled to bovine serum albumin (2-OA-BSA), an antigen selected following quantitative structure-activity relationship analysis of the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), the immunodominant autoantigen of PBC. Recent data in humans with PBC has suggested that a major component of liver pathology is due to activation of innate immunity. We took advantage of our 2-OA-BSA model and immunized mice with and without the addition of α-galactosylceramide (α-GalCer), an invariant natural killer T cell activator. Importantly, we report herein that 2-OA-BSA-immunized mice exposed to α-GalCer develop a profound exacerbation of their autoimmune cholangitis, including significant increases in CD8(+) T-cell infiltrates, portal inflammation, granuloma formation, and bile duct damage. Furthermore, such mice produce increased levels of antimitochondrial antibodies and have evidence of fibrosis, a feature not previously reported in the murine models of PBC. CONCLUSION: Our data suggests a primary role of innate immunity in the exacerbation of autoimmune cholangitis and also become a logical explanation for the recurrence of PBC following liver transplantation in the absence of major histocompatability complex compatibility. We submit that PBC begins with loss of tolerance to PDC-E2 and a multilineage antimitochondrial response in which autoreactive CD8(+) T cells are critical. However, the perpetuation of disease and its exacerbation will also be modulated by innate immune mechanisms.
UNLABELLED: Murine models of autoimmunity allow the study of the earliest events in disease pathogenesis. Our laboratory has developed a xenobiotic induced model of primary biliary cirrhosis (PBC) following immunization of mice with 2-octynoic acid coupled to bovine serum albumin (2-OA-BSA), an antigen selected following quantitative structure-activity relationship analysis of the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), the immunodominant autoantigen of PBC. Recent data in humans with PBC has suggested that a major component of liver pathology is due to activation of innate immunity. We took advantage of our 2-OA-BSA model and immunized mice with and without the addition of α-galactosylceramide (α-GalCer), an invariant natural killer T cell activator. Importantly, we report herein that 2-OA-BSA-immunized mice exposed to α-GalCer develop a profound exacerbation of their autoimmune cholangitis, including significant increases in CD8(+) T-cell infiltrates, portal inflammation, granuloma formation, and bile duct damage. Furthermore, such mice produce increased levels of antimitochondrial antibodies and have evidence of fibrosis, a feature not previously reported in the murine models of PBC. CONCLUSION: Our data suggests a primary role of innate immunity in the exacerbation of autoimmune cholangitis and also become a logical explanation for the recurrence of PBC following liver transplantation in the absence of major histocompatability complex compatibility. We submit that PBC begins with loss of tolerance to PDC-E2 and a multilineage antimitochondrial response in which autoreactive CD8(+) T cells are critical. However, the perpetuation of disease and its exacerbation will also be modulated by innate immune mechanisms.
Authors: Hiroto Kita; Shuji Matsumura; Xiao-Song He; Aftab A Ansari; Zhe-Xiong Lian; Judy Van de Water; Ross L Coppel; Marshall M Kaplan; M Eric Gershwin Journal: J Clin Invest Date: 2002-05 Impact factor: 14.808
Authors: S A Long; C Quan; J Van de Water; M H Nantz; M J Kurth; D Barsky; M E Colvin; K S Lam; R L Coppel; A Ansari; M E Gershwin Journal: J Immunol Date: 2001-09-01 Impact factor: 5.422
Authors: S Sharif; G A Arreaza; P Zucker; Q S Mi; J Sondhi; O V Naidenko; M Kronenberg; Y Koezuka; T L Delovitch; J M Gombert; M Leite-De-Moraes; C Gouarin; R Zhu; A Hameg; T Nakayama; M Taniguchi; F Lepault; A Lehuen; J F Bach; A Herbelin Journal: Nat Med Date: 2001-09 Impact factor: 53.440
Authors: Patrick S C Leung; Chao Quan; Ogyi Park; Judy Van de Water; Mark J Kurth; Michael H Nantz; Aftab A Ansari; Ross L Coppel; Kit S Lam; M Eric Gershwin Journal: J Immunol Date: 2003-05-15 Impact factor: 5.422
Authors: Hiroto Kita; Olga V Naidenko; Mitchell Kronenberg; Aftab A Ansari; Paul Rogers; Xiao-Song He; Frits Koning; Toshifumi Mikayama; Judy Van De Water; Ross L Coppel; Marshall Kaplan; M Eric Gershwin Journal: Gastroenterology Date: 2002-10 Impact factor: 22.682
Authors: A K Singh; M T Wilson; S Hong; D Olivares-Villagómez; C Du; A K Stanic; S Joyce; S Sriram; Y Koezuka; L Van Kaer Journal: J Exp Med Date: 2001-12-17 Impact factor: 14.307
Authors: Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung Journal: World J Gastroenterol Date: 2016-01-07 Impact factor: 5.742
Authors: Patrick S C Leung; Jinjung Choi; Guoxiang Yang; Elena Woo; Thomas P Kenny; M Eric Gershwin Journal: Expert Rev Mol Diagn Date: 2016-03-30 Impact factor: 5.225
Authors: C-H Chang; Y-C Chen; Y-H Yu; M-H Tao; P S C Leung; A A Ansari; M E Gershwin; Y-H Chuang Journal: Clin Exp Immunol Date: 2014-08 Impact factor: 4.330